A new report from the Social Market Foundation think tank argues that the UK’s National Health Service should switch to paying for medicines based on patient outcomes.
Facing opposition and delay to healthcare reform in Congress, Trump aims to pass an executive order to address drug pricing - but it contains the now familiar contradictions
Families affected by the rare muscle wasting disease Duchenne muscular dystrophy will still have to pay a huge premium for Emflaza, a newly-approved drug based on an old steroid that helps